Can vitamin K2 and D3 slow artery calcium buildup?
Yes, but the effect is small. In a 24 month randomized trial of 398 adults with severe coronary artery calcification, calcium scores rose by an average of 196 points on vitamin K2 plus vitamin D3 and 248 points on placebo, a gap of 52 points.
A coronary calcium score comes from a quick CT scan of the heart. The scan counts the hardened, calcium-filled plaque sitting in the walls of the heart arteries and reports it as a number in Agatston units. The higher the number, the more plaque a person has built up. Almost everyone with plaque sees that number climb year after year, and the authors of this trial note that how fast it climbs is a strong predictor of future cardiovascular events. So the question this trial asked was simple: can two cheap vitamins slow the climb?
What the data show
The trial enrolled people who already had a lot of calcium. Everyone had a score of at least 400 Agatston units, the median score at the start was 903, and 44 percent were already above 1000. Of the 398 people analyzed, 30 percent were women, and the median age was 71.
After two years, the vitamin group’s scores rose by 196 points on average and the placebo group’s by 248 points. That is a difference of 52 points in favor of the vitamins, which works out to about 21 percent less progression. The range around that difference makes the direction reasonably certain: the true gap is very likely between 24 and 79 points (95 percent confidence interval, 24 to 79 points lower). The benefit looked the same in men and women, and the same whether people started in the 400 to 999 range or above 1000.
A subgroup of 143 people also had CT angiography, a contrast scan that separates hard calcified plaque from softer noncalcified plaque. Total plaque volume grew by a similar amount in both groups, and there was no change in noncalcified plaque volume between them. The slowdown showed up only in calcified plaque, where the vitamin group gained 8 cubic millimeters less than placebo (very likely between 2 and 13 cubic millimeters less).
Dr. Kumar’s Take
That last detail matters more than the headline number. The obvious worry with any drug or supplement that “lowers” a calcium score is that it might just be turning hard, stable plaque into soft plaque, which is the kind more likely to rupture and cause a heart attack. That did not happen here. Noncalcified plaque did not rise, so the vitamins were not trading a safer plaque for a more dangerous one.
Now the part that keeps this from being a headline. A 52 point difference sits on top of a median starting score of 903. Both groups still got worse. Nobody’s arteries cleared out. And this trial measured a picture, not an outcome. It did not report whether fewer people had heart attacks, strokes, or died, which is the only question that finally matters. Faster calcium progression tracks with worse outcomes, but slowing a number by 21 percent for two years is a promising signal, not proof of fewer events.
How strong is the evidence?
The design is about as good as nutrition research gets. It was multicenter, randomized, double-blind and placebo-controlled, with people enrolled from February 2023 to February 2024 and non-contrast cardiac CT at baseline, 12 months and 24 months. The primary endpoint, change in calcium score at 24 months, was set in advance, and the sex and baseline-score subgroups were planned rather than fished out afterward.
The limits are about scope. Everyone had severe calcification already, so the result says nothing about people with a score of 50 or a score of zero. Two years is short for a disease that takes decades. The plaque composition analysis rested on 143 people, and only those with scores under 1000. And a follow-up scan is not a clinical outcome.
Practical takeaways
- The trial only enrolled adults whose calcium score was already 400 Agatston units or higher, so the 52 point slowdown is a result in that group and not a finding about anyone else.
- Do not read a slower calcium score as a fixed artery, since scores rose in both groups and the vitamins only narrowed the gap.
- If you take warfarin, vitamin K directly interferes with how that drug works, so any K2 supplement has to be cleared with the doctor managing your blood thinner first.
- The doses tested here were specific, 720 micrograms a day of K2 and 25 micrograms a day of D3, so a random multivitamin is not the same intervention.
Related Studies and Research
- Can vitamin K help protect your arteries from calcification?
- Vitamin K2 and heart health: a promising ally against artery calcification
- Single-dose psilocybin vs placebo: first double-blind depression trial
- Saffron extract improves sleep quality: randomized double-blind trial
Frequently Asked Questions
Does vitamin K2 reverse coronary artery calcification?
No. In this trial the calcium score went up in both groups, by 196 points with the vitamins and 248 points with placebo. Nothing in the data shows calcium leaving an artery. The realistic goal with a supplement like this is a slower rate of buildup, not a lower score than you started with. Anyone selling K2 as a way to clean out arteries is going well past what the evidence supports.
Do I need a calcium scan before considering this?
The trial only enrolled people with a score of 400 or higher, which is a level most people never reach, so without a scan there is no way to know whether you resemble anyone who was studied. A coronary calcium CT is fast and low dose, and it is generally considered for adults at intermediate risk where the decision about treatment is truly uncertain. If your score turns out to be zero, none of these results apply to you.
Is 720 micrograms of vitamin K2 a safe daily dose?
That dose ran for 24 months in this trial without the study being stopped, which is the practical evidence available. It is far above the amount anyone gets from food, and it belongs in the category of a tested intervention rather than a casual daily habit. The single hard contraindication is warfarin, where extra vitamin K works against the drug and can push clotting out of range. Anyone on that medication, or on any anticoagulant, needs a physician’s input before starting.
Bottom Line
In 398 adults who already had severe coronary calcification, two years of vitamin K2 plus vitamin D3 slowed the growth of their calcium score by 52 Agatston units, about 21 percent less progression than placebo, and did it without pushing plaque into the softer, rupture-prone form. That is a real, well-designed finding with a modest effect size and no outcome data behind it yet. It moves vitamin K2 and D3 from an interesting theory to a reasonable conversation with your cardiologist, and it does not yet move it to a recommendation.
